By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
PLX insiders were on both sides of the trade this year. Buys came to roughly $101,000 (one buyer), sales to $314 (one seller).
Bashan Dror (CEO) made the biggest buy, worth around $101,000. That includes C-suite money, which tends to get the most attention.
102 investment managers listed PLX in their latest 13F filings (Q2 2026); more funds bought than sold. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling PLX stock?
In the last 12 months Protalix BioTherapeutics, Inc. insiders made open-market purchases worth about $101,000 and sales worth about $314. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PLX?
The most recent open-market insider trade in PLX was filed on 2025-12-23.
How many institutions own PLX?
102 investment managers reported holding PLX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PLX?
No congressional trades in PLX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).